Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Merus BV

Healthcare US MRUS

NoneUSD
0.00(0%)

Last update at 2026-01-29T21:01:09.315650Z

Day Range

--
LowHigh

52 Week Range

19.8061.61
LowHigh

Fundamentals

  • Previous Close -
  • Market Cap3199.65M
  • VolumeNone
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-164.04499M
  • Revenue TTM38.34M
  • Revenue Per Share TTM0.70
  • Gross Profit TTM -107.83800M
  • Diluted EPS TTM-2.73

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -151.74700M -130.23500M -66.57700M -85.01000M -54.95700M
Minority interest - - - - -
Net income -154.93900M -131.19400M -66.81600M -85.51300M -55.15100M
Selling general administrative 59.84M 52.20M 40.90M 35.78M 34.11M
Selling and marketing expenses 2.54M - - - -
Gross profit -83.46102M 29.60M -37.16010M -27.39174M -18.50572M
Reconciled depreciation 2.23M 1.28M 1.49M 1.44M 1.14M
Ebit -156.54700M -160.03800M -89.97600M -75.87800M -58.65700M
Ebitda -154.00700M -184.77500M -113.15400M -65.00200M -60.27200M
Depreciation and amortization 2.54M -24.73700M -23.17800M 10.88M -1.61500M
Non operating income net other - - - - -
Operating income -156.54700M -160.03800M -89.97600M -75.87800M -58.65700M
Other operating expenses 200.49M 201.62M 139.08M 105.82M 89.79M
Interest expense 14.51M 2.72M 0.13M 18.56M 6.45M
Tax provision 2.54M 0.96M 0.24M 0.50M 0.19M
Interest income - 2.72M - 0.30M 1.89M
Net interest income 10.75M 2.72M -0.12900M 0.30M 1.89M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 3.19M 0.96M 0.24M 0.50M 0.19M
Total revenue 43.95M 41.59M 49.11M 29.94M 31.13M
Total operating expenses 197.95M 201.62M 139.08M 105.82M 89.79M
Cost of revenue 127.41M 11.98M 86.27M 57.33M 49.64M
Total other income expense net 4.80M 29.80M 23.40M -9.13200M 3.70M
Discontinued operations - - - - -
Net income from continuing ops -176.75800M -131.19400M -66.81600M -85.51300M -55.15100M
Net income applicable to common shares - -131.19400M -66.81600M -85.51300M -55.15100M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 458.49M 376.54M 456.60M 231.22M 263.38M
Intangible assets 1.80M 1.95M 2.35M 2.84M 2.88M
Earning assets - - - - -
Other current assets 9.66M 2.20M 2.17M 1.06M 4.95M
Total liab 102.15M 129.49M 140.40M 128.95M 132.08M
Total stockholder equity 356.34M 247.06M 316.20M 102.26M 131.30M
Deferred long term liab - - - - -
Other current liab 40.13M 37.99M 22.51M 22.01M 13.54M
Common stock 5.88M 4.75M 4.48M 3.21M 2.92M
Capital stock 5.88M 4.75M 4.48M 3.21M 2.92M
Retained earnings -753.06100M -598.12200M -466.92800M -400.11200M -314.59900M
Other liab - 38.77M 66.24M 79.69M 91.42M
Good will - - - - -
Other assets - 6.85M 2.50M 2.36M 2.19M
Cash 205.05M 147.75M 241.44M 163.08M 197.61M
Cash and equivalents - - - - -
Total current liabilities 69.09M 78.93M 71.90M 46.75M 36.79M
Current deferred revenue 22.68M 29.42M 34.66M 20.18M 18.84M
Net debt -192.88400M -134.27500M -237.68400M -159.12900M -192.36000M
Short term debt 1.67M 1.68M 1.49M 1.43M 1.38M
Short long term debt - - - - -
Short long term debt total 12.16M 13.47M 3.75M 3.95M 5.25M
Other stockholder equity 1126.05M 870.87M 787.87M 490.09M 441.39M
Property plant equipment - 24.84M 7.28M 8.02M 8.93M
Total current assets 368.81M 306.44M 424.18M 217.99M 247.37M
Long term investments 57.31M 36.46M 20.30M 0.00000M 2.01M
Net tangible assets - 245.10M 313.85M 99.42M 128.42M
Short term investments 150.13M 142.48M 168.99M 44.67M 42.15M
Net receivables 3.98M 4.70M 6.67M 1.75M 2.65M
Long term debt - - - - -
Inventory 0.00000M 9.31M 4.91M 7.43M -
Accounts payable 4.60M 9.83M 13.24M 3.13M 3.03M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -22.53300M -30.44800M -9.22100M 9.07M 1.59M
Additional paid in capital - - - - -
Common stock total equity - - - 3.21M 2.92M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 2.87M 4.81M 2.08M 1.95M 1.91M
Deferred long term asset charges - - - - -
Non current assets total 89.68M 70.10M 32.42M 13.22M 16.01M
Capital lease obligations 12.16M 13.47M 3.75M 3.95M 5.25M
Long term debt total - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -24.04700M 2.80M -146.62300M -1.48600M 26.77M
Change to liabilities - -29.91600M 19.85M -19.35600M -17.99000M
Total cashflows from investing activities - 2.80M -146.62300M -1.48600M 24.17M
Net borrowings - - - - -
Total cash from financing activities 230.09M 58.74M 281.95M 39.52M 74.23M
Change to operating activities - 9.12M 1.01M 4.13M 2.18M
Net income -154.93900M -131.19400M -66.81600M -85.51300M -55.15100M
Change in cash 56.60M -93.31000M 78.47M -34.53000M 33.08M
Begin period cash flow 148.45M 241.75M 163.28M 197.81M 164.73M
End period cash flow 205.05M 148.44M 241.75M 163.28M 197.81M
Total cash from operating activities -142.20700M -149.89900M -59.62700M -79.90100M -63.04800M
Issuance of capital stock 225.71M 57.74M 265.11M 38.07M 74.18M
Depreciation 2.54M 1.28M 1.49M 1.44M 1.14M
Other cashflows from investing activities - - - - 26.77M
Dividends paid - - - - -
Change to inventory - - 1.03M 4.13M 2.29M
Change to account receivables 1.73M 1.83M -4.99100M 1.15M 0.63M
Sale purchase of stock - - -0.28500M - 74.23M
Other cashflows from financing activities -0.44500M 1.00M 17.13M 1.45M 0.05M
Change to netincome - -1.02400M -10.16900M 18.25M 6.15M
Capital expenditures 3.98M 7.64M 0.87M 1.29M 2.60M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -25.75300M -18.96600M 15.87M -14.07900M -15.18100M
Stock based compensation 26.23M 24.54M 17.09M 9.37M 7.83M
Other non cash items 8.88M -23.93500M -27.25300M 9.00M -1.59900M
Free cash flow -146.18900M -157.53800M -60.49700M -81.18800M -65.64600M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
MRUS
Merus BV		 - -% - - - 55.89 6.89 48.11 -13.7296
NVO
Novo Nordisk A/S		 1.81 4.32% 43.81 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.78 4.23% 44.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 12.68 2.96% 441.01 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 6.44 1.04% 625.39 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

Merus BV

Uppsalalaan 17, Utrecht, Netherlands, 3584 CT

Key Executives

Name Title Year Born
Dr. Sven Ante Lundberg M.D. CEO, Pres, Principal Financial Officer & Exec. Director 1963
Mr. Peter B. Silverman J.D. Exec. VP, Gen. Counsel, Chief Intellectual Property Officer and Head of Utrecht & US Legal 1978
Mr. Hui Liu Ph.D. Chief Bus. Officer, Exec. VP & Head of Merus U.S. 1967
Dr. Hennie Hoogenboom Co-Founder and Scientific Advisor NA
Harry Shuman Chief Accounting Officer NA
Mr. Cornelis Adriaan de Kruif Ph.D. CTO & Exec. VP 1965
Dr. Cecilia Anna Wilhelmina Geuijen Ph.D. Chief Scientific Officer & Sr. VP NA
Ms. Jillian Connell VP of Investor Relations & Corp. Communications NA
Mr. Alexander Berthold Hendrik Bakker Ph.D. Chief Devel. Officer & Exec. VP 1967
Dr. Andrew Joe M.D. Chief Medical Officer & Sr. VP 1967

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.